Aberrant induction of human leukocyte antigen-G (HLA-G) expression has been observed in various malignancies and is strongly associated with tumor immune escape, metastasis and poor prognosis. To date, great achievements have been made in understanding the underlying mechanisms of HLA-G involved in tumor progression. HLA-G could lead to tumor evasion by inhibition of immune cell cytolysis, differentiation and proliferation and inhibition of cytokine production, induction of immune cell apoptosis, generation of regulatory cells and expansion of myeloid-derived suppressive cells and by impairment of chemotaxis. Moreover, HLA-G could arm tumor cells with a higher invasive and metastatic potential with the upregulation of tumor-promoting factor expression such as matrix metalloproteinases (MMPs), indicating that ectopic HLA-G expression could render multiple effects during the progression of malignancies. In this review, we summarized the mechanisms of HLA-G involved in promoting tumor cell immune escaping, metastasis and disease progression. Special attention will be paid to its significance as an attractive therapeutic target in cancers.
more frequently observed in tumor lesions with advanced stage and its clinical relevance has been addressed (5, 14) . HLA-G can directly inhibit immune cell function through receptor binding and/or through trogocytosis and impairment of chemotaxis (15, 16) ; moreover, HLA-G can render tumor cells with a higher invasive, metastatic potential and an unfavorable prognosis in tumor patients, indicating that HLA-G expression has multiple effects including promoting tumor cells to escape immune surveillance and enhancing their metastasis during the progression of malignancies (17) (18) (19) . Therefore, the role of HLA-G in malignancies has gained considerable clinical interest for the possibility of exploiting it as a molecular biomarker and a therapeutic target.
MECHANISMS OF HLA-G INVOLVED IN TUMOR IMMUNOLOGY
HLA-G expression could render multiple effects during the progression of malignancies, such as inhibiting immune cell cytolysis, inducing immune cell apoptosis and the generation of regulatory cells through receptor binding and/or trogocytosis, and impairing chemotaxis of different immune effector where four of them are membrane-bound (HLA-G1 to -G4) and three soluble (HLA-G5 to -G7) (5) . Moreover, another soluble isoform termed "shed HLA-G1" can be generated by proteolytic cleavage of the membrane-bound HLA-G1 by metalloproteinases (6) .
HLA-G expression was first observed in cytotrophoblasts (7) . In physiological conditions, HLA-G expression was also found in erythroid precursors, cornea, thymic medulla and pancreatic islets (8, (9) (10) (11) . However, HLA-G can be neoexpressed in pathological conditions including cancers, transplantation, and inflammatory and autoimmune diseases and viral infections (3, 5, 12, 13) .
In malignancies, ectopic induction of HLA-G expression has been observed in various types of tumors where it was
INTRODUCTION
The pace of tumor growth is dictated by the continuous interaction between cancer cells and the host immune system. With the selection pressure exerted by immune system, various strategies have been developed and applied by tumor cells to avoid recognition and destruction by different immune effectors (1, 2) . One of the common strategies used by tumor cells to escape innate and adaptive immune response is associated with an induced aberrant expression of the nonclassical class I molecule human leukocyte antigen-G (HLA-G) (3) .
HLA-G is the best characterized nonclassical HLA-class Ib molecules, which includes HLA-E, -F and -H (4). Due to its primary mRNA alternative splicing, seven HLA-G isoforms can be generated, Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy cells, and that this protective effect could be reversed by masking HLA-G antigens using HLA-G or its receptor-specific antibody (18, (38) (39) (40) . It has been demonstrated that soluble HLA-G (sHLA-G) could inhibit B-cell proliferation, differentiation and immunoglobulin (Ig) secretion in both T-cell-dependent and -independent models of B-cell activation through the receptor ILT2 (41) . To be noted, HLA-G5 was shown to inhibit phagocytosis and reactive oxygen species production of neutrophils through ILT4 (42) .
Indirect inhibitory immune effects of HLA-G could induce the generation cytotoxicity by interacting with the ILT2 inhibitory receptor (32) (33) (34) (35) . We recently reported that NK cell cytolysis inhibited by HLA-G1 in an expression proportion-dependent manner, and HLA-G1 and HLA-G5 isoforms have an additive inhibitory effect on NK cytolysis (36, 37 
RELEVANCE OF HLA-G EXPRESSION IN CANCERS
The expression of HLA-G in cancer was first demonstrated in the context of melanoma (57) . Since then, HLA-G expression in more than 2,000 malignant samples among thirty types of tumors including both solid and hematological malignancies has been studied, where HLA-G expression was observed in different sources such as on the cell surface, secreted or in tumor-derived exosomes (14, 58) . Among these studies, there is a high frequency of tumor cell-surface HLA-G expression with an absence in healthy tissue, and increased sHLA-G levels has been detected in various body fluids in a variety of cancers (14) . Expression of HLA-G was found to be correlated with clinical parameters such as more advanced disease stage, tumor metastasis and/or with a worse prognosis in tumor patients, indicating that HLA-G could facilitate tumor immune escape, invasiveness and metastasis; thereby HLA-G expression was found to be associated with advanced clinical stage and disease progression and HLA-G expression was also documented as an unfavorable prognostic factor for many kinds of solid malignancies, including breast cancer (59) (60) (61) (62) (63) (64) , colorectal cancer (65, 66) , cervical cancer (67, 68) , endometrial of allogeneic skin graft survival (52) . In an immunocompetent HLA-G1 + M8
(a human melanoma cell line) tumorbearing mouse model, interaction between HLA-G and the murine receptor PIR-B could expand the population of CD11b + Gr1 + PIR-B + MDSC, which could decrease NK cytotoxic activity (19) . In another study, in a mouse model with murine mammary 4T1 cell line, HLA-G5 was observed to favor the CD11b + Ly6G
Trogocytosis is a process of transferring cell-surface membrane proteins and membrane patches from one cell to another during contact. (20, 46) . A novel subset of tolerogenic DCs (DC-10), which secrete high levels of IL-10, and express high levels of HLA-G and its receptors ILT2, ILT4 and ILT3, has a potent specific function to induce IL-10-producing adaptive Tr1 through the ILT4/HLA-G signaling pathway. Data showed that the high expression levels of ILT4, HLA-G and IL-10 are necessary for the tolerogenic activity of DC-10 and their ability to prime T cells to become Tr1 cells (47) . Recent data showed that HLA-G-expressing DC-10 and CD4 + T cells are highly represented in acute myeloid leukemia (AML) patients with HLA-G positive blasts (48) . MDSC are present in cancer patients and tumor-bearing mice and are, in part, responsible for the inhibition of the cell-mediated immune response against the tumor (49) . It has been shown that infiltration of MDSCs in solid tumors is associated with poor prognosis as circulating MDSCs have a negative impact on survival and inversely correlate with the presence of functional antigen-specific T cells in patients with advanced melanoma (50, 51 Other than the tolerant functions of HLA-G in tumor immune escaping, HLA-G was also found in association with the status of tumor invasion and metastasis in patients and preclinical models with the mechanism of upregulating the expression of MMPs (18, 106) (Figure 2 ). MMPs are one of the central mediators of the biology of tumor invasion and metastasis with their ability to degrade basement membrane and extracellular matrix components (107) . Indeed, the relationship between HLA-G and MMP expression was addressed in previous studies. Hiden et al. (108) addressed that MMP-15 expression could be induced by TNF-α only in the HLA-G positive first trimester human trophoblast cell line ACH-3P, and only the HLA-G positive extravillous trophoblasts (EVT) have the invasive potential. Much higher MMP-14 expression was also found in HLA-G positive first-trimester invasive trophoblasts (109) . Both tumor cells and EVT share similar characteristics in many regards, such as the capability myelomas (OPM-2, LP1 and RPMI 8226), and B cell leukemia (BV173). These data imply that HLA-G could be correlated with a good prognosis by inhibiting the proliferation of ILT2-expressing tumor cells. Other factors may also account for these controversial results, including differences in expression and interaction of ILT2 and HLA-G by tumor cells, and effects of different chemotherapy status on HLA-G expression between the studies.
To be noted, regulation of HLA-G expression is controlled at the epigenetic, transcriptional and posttranscriptional level. The polymorphic variations in the 5′ upstream regulatory region (5′ URR) and 3′ untranslated regions (3′ UTR) in the HLA-G gene were reported to affect the HLA-G mRNA translation and HLA-G expression by microRNA binding and/or by modifying mRNA stability (101) . In this context, a possible association of HLA-G gene polymorphism with susceptibility and/or clinical outcome of malignancies was documented. A 14-base pair insertion/deletion (ins/del) polymorphism (rs66554220) in the 3′ UTR was revealed; both chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) patients with the del/del genotype had shorter survival than patients with the ins/del or ins/ ins genotype (102, 103) . Additionally, DLBCL patients who carry the HLA-G-725CC genotype in the 5′ URR had a significantly higher probability of overall survival than individuals with other genotype combinations of HLA-G-725C/G/T (103). Furthermore, in the coding segment of the HLA-G gene, the codon 130C deletion occurrence was observed to be significantly associated with a decreased free disease and overall survival in nasopharyngeal carcinoma patients (104) . However, more studies on the complete HLA-G gene and its linkage disequilibrium with other genes and on HLA-G expression at both the tumor site and plasma in a specific microenvironment are required to consolidate these findings. carcinoma (69, 70) , esophageal squamous cell carcinoma (71) (72) (73) (74) , gastric cancer (75) (76) (77) , glioblastoma (78) , hepatocellular carcinoma (79) (80) (81) , lung cancer (82) (83) (84) , nasopharyngeal carcinoma (85) , oral cavity squamous cell carcinoma (86) , ovarian cancer (87-89), pancreatic adenocarcinoma (90), thyroid carcinoma (91, 92) . These data were summarized in Table 1 . Moreover, HLA-G expression was found to distinguish metastatic from nonmetastatic endometrial carcinoma (69) . In our recent study, we found lesion HLA-G5/-G6 isoform expression could discriminate adenocarcinoma from squamous cell carcinoma in lung cancer patients, where tumor cell sHLA-G expression was predominately observed in adenocarcinoma lesions (84) . These data indicated that lesion HLA-G or specific HLA-G isoform expression may serve as a clinical marker for tumor metastasis or types of histopathological discrimination.
Although HLA-G expression in solid tumors as mentioned above was associated with an unfavorable outcome or prognosis, no clear correlation was established between HLA-G expression and unfavorable clinical outcome in hematological malignancies, thus the clinical significance of HLA-G expression in liquid tumors remains controversial (93) (94) (95) (96) (97) (98) (99) , as presented in Table 2 .
The discrepancy in the clinical significance of HLA-G between solid and liquid tumors may be due to the nature of the tumor cells which, in malignant hematological diseases, are immune cells capable of expressing the HLA-G inhibitory receptor. In this context, studies by Naji et al. (41, 100) revealed that, through interaction with ILT2, HLA-G could inhibit the proliferation, differentiation and antibody secretion of activated B cells originating from peripheral blood and secondary lymphoid organs, such as tonsils, and HLA-G could also inhibit the proliferation of ILT2-bearing neoplastic B cell lines such as human B cell lymphomas (Raji, Daudi and Ramos), multiple 
501 IHC (4H84) 60% HLA-G expression is unrelated to relapse free period or overall survival in the whole cohort; however, among classical HLA class I negative patients, HLA-G expression is a prognostic factor.
52 IHC (5A6G7) 59.6% HLA-G is associated with immune response evasion and breast cancer aggressiveness.
45
HLA-G expression is associated metastasis in lymph nodes and with shorter survival time.
Colorectal cancer 201 IHC (HGY) 64.6% HLA-G is an independent prognosis factor. (65) 102 IHC (MEM-G/2) 70.6% HLA-G expression has a significantly poorer overall survival than those without HLA-G expression.
Cervical cancer 58 IHC (5A6G7) 75.86% HLA-G expression might be an early marker for assessing the progression of cervical lesion progression. 
131 IHC (5A6G7) 34% HLA-G was predominately expressed in lung adenocarcinoma, which could be a useful biomarker to discriminate adenocarcinoma from squamous cell carcinoma in NSCLC patients.
Continued on the next page 
Ab, antibody; ALL, acute lymphoblastic leukemia; RT-PCR, reverse-transcription PCR; AML, acute myeloid leukemia; B-cell chronic lymphocytic leukemia (B-CLL); FCM, flow cytometry. a MEM-G/9, detecting native form of human HLA-G1 on cell surface as well as with soluble HLA-G5 isoform in its beta2-microglobulin associated form. (15, 113, 114) .
decrease the MMP-2 and MMP-9 mRNA and protein expression dramatically (21) .
IMPLICATIONS FOR HLA-G-BASED STRATEGIES IN CANCER IMMUNOTHERAPY
Since HLA-G is frequently and specifically expressed on tumor cells, and its expression is associated with unfavorable prognosis in various malignancies, HLA-G is an attractive target for cancer therapies (15, 111) .
Taking the journey of HLA-Gexpressing malignant cells and targeting of proliferation, invasion, vasculogenic mimicry, angiogenesis and systemic immune modulation (110) . Therefore, similar tactics may be involved in invasion and metastasis of tumor cells.
Using a Balb/c nu/nu model, we reported that with exogenous HLA-G expression the ovarian cancer cell HO-8910 has a higher invasion and metastasis potential and the host is much less likely to survive, suggesting for the first time that HLA-G expression is associated with tumor metastasis and with poor survival in an animal model in vivo (18) . Characterization of the mechanisms by which HLA-G is involved in tumor cell invasion and metastasis shows that upregulated MMP-15 expression was in accordance with HLA-G expression and a strong correlation was also observed between HLA-G and MMP-15 expression in a cohort of ovarian cancer lesions. Furthermore, knockdown of the HLA-G-induced MMP-15 expression significantly decreased cell migration and tumor metastasis (18) . In accordance with our findings, HLA-G5 was documented to stimulate primary trophoblasts and trophoblastic cell line (JAR and JEG-3) invasion and to increase MMP-2 transcripts and their activity by binding to KIR2DL4 and ILT2 (22) . In another study, suppression of HLA-G expression in JEG-3 cells was observed to 
